Copy of `Sport Science Undergrad - Sporting terms`

The wordlist doesn't exist anymore, or, the website doesn't exist anymore. On this page you can find a copy of the original information. The information may have been taken offline because it is outdated.

Sport Science Undergrad - Sporting terms Category: Health and Medicine Date & country: 27/07/2014, USA Words: 68

uncertainty
Molecular Medicine

white space
Financial Related term

R&D productivity
This report examines the convergence of scientific, regulatory, social, political, and economic factors that are inhibiting the development of new molecular entities (NMEs), resulting in the current discovery deficit that threatens the pharmaceutical industry and the delivery of healthcare as we know it. ...offers potential solutions toward securing the future of innovative drug discovery and development. Insight Pharma Reports, Pharmaceutical R&D Productivity

Supplementation


technology audit
Assessment of a company's technology, present and future needs (including user training), capabilities, and impact upon the core competencies.

technology integration
Easier said than done.

technology transfer
Legal and Intellectual property

time to market
A major consideration for strategic planning in the pharmaceutical industry.

strategies
The pharmaceutical industry thrives on innovative products and clinically differentiated medicines that can create real value. Innovation has the greatest impact on a pharmaceutical company

strategic resource management
Strategic Resource ManagementStrategic Resource Management October 21-22, 2013 Bethesda, MD Program

stage gate criteria
Process for making periodic go/no go decisions in R&D standards

spin-offs
Large(r) companies may find spinning off smaller divisions (or newly acquired ones outside their core competencies) makes more sense than trying to integrate different companies and cultures. Some spin- offs eventually become larger than the parent. Johnson & Johnson is noted by Clayton Christensen in his Innovator's Dilemma as being particularly good as spinning off a number of successful enterprises. Related term

SOPs standard operating procedures
This report focus on standard operating procedures SOPs relevant to backup compound strategies and tactics. Here SOPs do not mean rigid protocols. Rather they are more like templates into which factors specific to the market opportunity in question are inserted to help decide the ideal approach to backups and to provide higher management with information needed for decisions on resource allocations in and among therapeutic areas. Insight Pharma Reports, Backup Compound Strategies

specialty pharmaceuticals
Targets a small- medium population disease with high unmet medial need. Often a large molecule injectable. Insight Pharma Reports Specialty Pharmaceuticals

proof of principle
Proof of principle research aims to provide evidence for the impact of new, alternative disease control tools and approaches. On the basis of such evidence, current disease control strategies may be improved. Research and Training in Tropical Disease, WHO http://www.who.int/tdrold/topics/pop/default.htm

reimbursement
Generating Evidence for Reimbursement Decisions

Related term
Molecular medicine glossary uncertainty

Related terms
biotechnology industry, blockbuster drugs, market fragmentation.

process optimization
Rather than focusing on technology alone, companies must closely examine workflow, capacity and communication to optimize discovery much as one might optimize a manufacturing process. Benchmarking performance at multiple points within drug discovery and development is an essential pre- requisite to process optimization.

proof of concept
Evidence that demonstrates that a business model or idea is feasible. Investorwords http://www.investorwords.com/p5.htm#proofofconcept

pricing
Comparative case studies of market launch, market access, and product pricing strategies for a variety of cancer drugs and companion diagnostics. Effective and sustainable commercialization strategies will be discussed. Pricing, Reimbursement and Market Access for Targeted Cancer Therapies November 6-7, 2012 Philadelphia, PA Program

Protein Synthesis
the process whereby DNA encodes for the production of amino acids and proteins through processes known as transcription and translation. Usually in a sporting context when protein synthesis is discussed it refers to the production of protein for muscle fibres.

price trends - prescription drugs
The purpose of this report is to examine pricing dynamics for prescription drugs for recent years. The prices of new drugs will be analyzed over time and by factors that may be associated with launch prices. Price trends for 1995 to 1999 will also be examined by therapeutic category for a number of major categories (in terms of expenditure levels or growth) with well- defined subclasses that can be analyzed individually and compared on the basis of the age of the category. The pricing of generic substitutes in these therapeutic categories will also be provided for comparative purposes. Finally, launch prices during the study period for new entrants to existing subclasses within the therapeutic categories will be examined and compared to the prices of the incumbents in the subclass. The results show that new drugs can vary substantially in their impact on drug expenditures. Some drugs are introduced at significant discounts to existing drugs that are highly substitutable with the new drug. In addition, while entirely new classes of compounds to treat a disease or condition are often priced at a premium relative to older classes, this is not always the case. The data also suggest that new drug prices tend to reflect the degree of price sensitivity in the market and the perceived value of the product to patients. Finally, average price increases over time for the pharmacologic and chemical classes examined varied in all directions in relation to general price inflation. However, most class price increases were similar to economy- wide inflation rates. Joseph A. DiMasi, PRICE TRENDS FOR PRESCRIPTION

Protein Breakdown
also known as protein catabolism or protein degradation, the breakdown of proteins into smaller amino acids or peptides. When protein breakdown is discussed in sport it usually refers to the rate that muscle protein is broken down.

portfolio management
Portfolio ManagementPortfolio Management October 22-23, 2013 Bethesda, MD Program

pharmaceutical industry
The pharmaceutical industry thrives on innovative products and clinically differentiated medicines that can create real value. Innovation has the greatest impact on a pharmaceutical company

pharmagraphics
The emerging discipline of understanding how different segments of the population relate to their health information needs. How do factors such as age, income, education or disease indication affect consumer behavior and preferences? How can a better understanding of these segments be used effectively to improve the impact of promotional and educational spending allocations between different channels and campaigns Related term

partnering
See Financials partnering

outsourcing
Within the past several years, a number of government labs as well as private and joint venture CRO

Nutrition
The relationship between food and those who eat it. For sport this means looking at how an athletes dietary needs to try and achieve maximal performance.

organization of pharmaceutical R&D
By far the most common organizational structure within pharmaceutical R&D is based on therapeutic indications. As target pathways and target families become better recognized as opportunities for synergistic development that cut across disease indications, what are the implications for how best to capture this synergy? As molecular tools are increasingly applied beyond target biology to more of the entire development process, how can expertise in specific tools best be leveraged across different departments? As chemistry and biology become more intertwined, how can researchers trained in one discipline or the other learn to better communicate with each other? As researchers trained in reductionist techniques and used to working on small projects become involved in much larger systems biology and high throughput chemistry projects, how does this change the nature of the work they do? What organizational structures and policies may facilitate optimal performance under these changing conditions?

niche busters
with increased competition from generic drugs, sky-rocketing costs of marketing blockbusters and declining support from regulators, pharmaceutical companies are starting to shift their growth strategies away from blockbuster drugs and on to niche-centric drugs. Niche-busters, as they are being labeled, face less competition and lower marketing costs. The value of theses niche-buster drugs grows significantly when an increased focus on research and development yields faster development times. Champions 2.0, Issy Goldwasser, Symyx Technologies, BioIT World 2007 http://www.bio-itworld.com/issues/2007/march/champions/symyx/

neuroeconomics
A highly synthetic and interdisciplinary effort to understand how both humans and animals make decisions. ,,It now seems clear that every day, at every action, our brains unconsciously compute and store the values of every event that befalls us. ,, What we are trying to do is to combine economics, psychology, and neuroscience into a single descriptive model that explains how we make choices. Paul Glimcher, Decision making and the brain http://www.amnh.org/news/2011/01/decision-making-and-the-brain/#more-2760

multibusters
Multiple drugs for a single indication, efficacious in identifiable sub- populations. Related term

market research
Can be difficult to impossible to find data in emerging sectors and for disruptive technology. Related term

megabrands
According to AstraZeneca, a megabrand is a product that has the following characteristics

milestones
Specific business accomplishments, often tied to funding sources.

market forecasting- pharmaceutical
Accurately forecasting the market potential for new compounds is becoming an essential tool in long- term strategic planning, as it aids in various decisions that are pivotal to the survival and success of a biotech or pharmaceutical company. Forecasting is used in many situations

hypercompetitive
In Richard A. D'Aveni's Hypercompetitive Rivalries

incubators
The United States is home to the world

innovators
Research pharmaceutical

KOL Key Opinion Leader
Thought leaders, an important part of many pharmas marketing strategies. May be global, national, regional or local.

life cycle management
Successful drugs follow a typical pattern of heavy up- front investment in development, followed by market penetration and peaking sales, followed by a decline in the face of follow- on drugs or generics. A number of approaches can be used to alter the shape of this revenue curve, including second- generation follow- on compounds, extended life through formulation and drug delivery enhancements, outcome studies and management of the generification process. Some steps can be taken early to maximize the benefits of drug life cycle management.

For most of Lilly
Evidence and Implications of a Global R&D Network Sidney Taurel Chairman

free market
vs. price controls. CHA, Cambridge Healthtech Advisors, Strategic Considerations for the US Pharmaceutical Industry report, 2005

Healthcare
Baker Library Guide, 2005 http://www.library.hbs.edu/guides/healthcare/

elevator pitch
Sound bite version of your business plan. Advice on from the MIT Enterprise Forum http://www.mitforumcambridge.org/archive/r_apr00.html#editor

EphMrA
European Pharmaceutical Marketing Research Association http://www.ephmra.org/

fail fast
A term that makes people in drug discovery and development wince, but considering the costs of later failures, it looks more and more like an important option.

drug repositioning
Drug discovery & development

drug development - costs
The fully capitalized cost to develop a new drug, including studies conducted after receiving regulatory approval, averages $897 million, according to an analysis by the Tufts Center for the Study of Drug Development. The announcement expands on the $802 million estimate released by the Tufts Center in November 2001, by including post-approval R&D costs. The $802 million figure includes total average preclinical and clinical costs up to the time of receiving FDA marketing approval. Estimates are in year 2000 dollars. Joseph DiMasi et. al, Tufts CSDD, May 13, 2003 http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=29

disruptive technologies
Some technology improvements are linear or incremental. Others truly change the paradigm. Harvard Business School faculty member Clayton Christensen's Innovator's Dilemma (1997) analysis (of data from the disk drive industry) found disruptive technologies are much cheaper than existing ones. Big mainstream companies were quite capable of developing these technologies (and had). What they couldn't do was figure out how to market them (and justify devoting sufficient resources to them). The pharmaceutical industry is mentioned only in passing, but the success of larger established companies either partnering with smaller less established ones (clearly happening in the pharmaceutical and biotechnology sectors) or spin- off of promising developments as separate companies (Johnson & Johnson said to be particularly good at this) makes a lot of sense. Related term

disintermediation
An Internet term referring to the removal of intermediaries in a commercial transaction. The trend toward disintermediation in healthcare will actually arise from the application of the Internet to healthcare. In one example, Orchid Bioscience announced GeneShield.com an Internet- based genetic testing service to identify people with mutations that could trigger side effects or reduce the efficacy of certain widely- prescribed drugs. Use of this service can potentially place more knowledge and decision power in the hands of the consumer. There are at least a half dozen of these websites with business models similar to GeneShield.com, all directed to the consumer. CHI Summit Report Transforming the Pharmaceutical Industry 2001

compound annual growth rate
Forecasting.

concentration ratios
http://www.agbioforum.org/v6n3/v6n3a07-oehmke.htm

convergence strategies
Finding new combinations of formerly distinct market segments for a company

corporate DNA
A company's core values, culture, personality, etc., that supposedly gets passed along to all new employees. Corporate DNA, however, is actually altered slightly every time a new person is hired. And a wholesale shift can occur by simply replacing the CEO. Nominated by Laurel Sutton. Buzzwords, Buzzwhack, 2002 http://www.buzzwhack.com/buzzcomp/indac.htm

competitive intelligence CI
the process of monitoring the competitive environment and analyzing the findings in the context of internal issues, for the purpose of decision support. CI enables senior managers in companies of all sizes to make more-informed decisions about everything from marketing, R&D, and investing tactics to long-term business strategies. Effective CI is a continuous process involving the legal and ethical collection of information, analysis that does not avoid unwelcome conclusions, and controlled dissemination of actionable intelligence to decision makers. Strategic and Competitive Intelligence Professionals http://www.scip.org/content.cfm?itemnumber=2214&navItemNumber=492

biotechnology industry
Developers of technology promoting drug development, disease treatment, and a deeper understanding of living organisms. Includes human, animal, and industrial biotechnology products and services. Also included are biosensors, biotechnology equipment, and pharmaceuticals. PriceWaterhouseCoopers MoneyTree Survey definitions, 2003 http://www.pwcmoneytree.com/moneytree/nav.jsp?page=definitions

blockbuster drugs
At CHI

business models - R&D
When considering the R&D productivity crisis it is imperative that current thinking, processes and models be challenged. For example, does the current strategy to align R&D by therapeutic area need to be further enhanced or do we chart a different course? The focus will not be on tools or technology for the promises of technology have arrived. The next wave of strategic thinking needs to be around business models and structures. Additionally, the impact of globalization on these evolving models must be understood and leveraged in order to successfully take the next step forward.

biotechnology
Biologics

bioentrepreneur
Nature Publishing Group's portal dedicated to scientists interested in commercializing their research. . http://www.nature.com/bioent/index.html

biomedical companies
Relation[s] to SIC/ NAICs codes?

best practices
This digest was created to assist biosciences industry partners and their economic development practitioners in identifying key state legislative and administrative efforts needed to create, nurture and retain the bioscience industry. The policies and legislation cited in this document are key examples of state efforts to grow and sustain bioscience industry development. Biotechnology Industry Organization, http://www.bio.org/local/industryDev/

adaptive design
Modeling innovative methods of forward-looking companies, Adaptive Design empowers management to create solutions to problems as they happen on the front line. These small changes lead to progressively better care at lower cost. When a patient doesn

applied research
Research pharmaceutical

benchmarking
The first step in process optimization is benchmarking. By measuring performance at various stages of drug discovery and development, from individual tasks to programs, benchmarking can help identify processes that are not functioning as intended. It enables companies to pinpoint unwanted delays between processes and evaluate the effectiveness of newly implemented technologies and strategies. Narrower term